Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from NanoVibronix ( (NAOV) ) is now available.
On May 14, 2025, NanoVibronix, Inc. announced the pricing of an underwritten public offering, issuing 400,000 shares of Series G Convertible Preferred Stock and warrants to purchase up to 4,901,982 shares of common stock. The offering, which closed on May 16, 2025, raised approximately $10 million in gross proceeds. The company plans to use the funds for debt redemption and general corporate purposes. This strategic move is expected to strengthen NanoVibronix’s financial position and support its ongoing operations and development initiatives.
More about NanoVibronix
NanoVibronix, Inc. is a medical technology company specializing in non-invasive and minimally invasive therapeutic devices. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the company focuses on acoustic-based therapeutic technologies such as PainShield® and UroShield®, and the ENvue™ Navigation Platform for medical applications including biofilm disruption, pain treatment, and feeding tube placement.
Average Trading Volume: 2,820,361
Technical Sentiment Signal: Sell
Current Market Cap: $3.15M
For detailed information about NAOV stock, go to TipRanks’ Stock Analysis page.